PDA

View Full Version : Lung Cancer Forum


  1. New Survival Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung
  2. New England Journal of Medicine Avastin in Lung Cancer
  3. Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical
  4. Introgen's INGN 241 Shows Synergy With Heat Shock Protein Inhibitors
  5. Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung
  6. Do cigarette warning labels work -- results from 4 countries
  7. Lung Cancer
  8. Lung cancer rates higher among female nonsmokers than previously
  9. Geron’s GRN163L Headed to Phase I Clinical Trials in Lung Cancer Patients
  10. Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Survival
  11. Phase II Trial Results Positive in Non-small Cell Lung Cancer For AS1404
  12. Functional profiling with cell culture assays
  13. Computed tomography screening may increase lung cancer diagnosis, but not decrease ri
  14. Study shows no survival benefit for CT screening for lung cancer
  15. Lung cancer risk reduced in female textile workers exposed to endotoxin
  16. Measuring lung motion leads to better radiation treatment for lung cancer
  17. Study reveals how some molecules inhibit growth of lung cancer cells
  18. Blood pressure drug shows potential as lung cancer treatment
  19. One WWOX Isn't Enough (To Protect Against Cancer)
  20. PF-3512676 (CPG 7909) Non-Small-Cell-Lung Immuno-modulatory Treatment Development His
  21. Where did all the Tobacco Settlement Money Go?
  22. Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
  23. Ireland Cancer Center researchers advance lung cancer treatment
  24. Assessment model based on medical history gauges lung cancer risk
  25. Study confirms the risk of exposure to secondhand tobacco smoke outdoors
  26. FDG-PET Imaging Clearly Predicts Lung Cancer Patients Response to Chemotherapy
  27. Hexavalent chromium in drinking water causes cancer in lab animals
  28. Talcum powder stunts growth of lung tumors
  29. Chemotherapy Resistance Testing in Lung Cancer Patients
  30. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
  31. Surgeons say minimally invasive lung surgery should be standard care
  32. Kids show signs of addiction after inhlaing one cigarette
  33. Targeted Cancer Therapy Improved with Ex-Vivo Chemosensitivity Analysis
  34. Defects in critical gene lead to accelerated lung tumor growth
  35. New technique detects specific chromosomal damage, may indicate lung cancer risk
  36. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
  37. Preventing lung scarring may extend lives of lung cancer patients
  38. Smac-ing Lung Cancer to Death
  39. Novel MRI technique shows secondhand smoke damages lungs
  40. lung cancer diagnoses can be significantly improved and followed with PET scanning
  41. M. D. Anderson research links diet, gardening and lung cancer risk
  42. Study points to possibility of blood test to detect lung cancer
  43. New report estimates 12 million cancer cases worldwide
  44. Why Do Some Lung Cancers Stop Responding to Tarceva?
  45. Cigarettes leave deadly path by purging protective genes
  46. Nexavar Dropped From Lung Cancer Trial
  47. 'Enormous Progress' In Reducing Cancer Does Not Include Lung Cancer
  48. Smoking's Effects On Genes May Play A Role In Lung Cancer Development And Survival
  49. Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More
  50. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Ca
  51. Researchers develop new method to test for lung cancer
  52. Mouth may tell the tale of lung damage caused by smoking
  53. Chemotherapy Does Not Improve Treatment For Mesothelioma
  54. Mayo Clinic researchers find common gene disorder doubles risk of lung cancer, even a
  55. Tarceva Delivers Benefits Across Broad Range Of NSCLC Cancer Patients
  56. New clinical trial for patients with asbestos-associated lung cancer
  57. Circulating tumor cells can reveal genetic signature of dangerous lung cancers
  58. Group Warns of Looming Thoracic Surgeon Shortage
  59. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
  60. Parental warning: second-hand smoke may trigger nicotine dependence symptoms in kids
  61. Smoking and solid fuel use in homes in China projected to cause millions of deaths
  62. Tobacco use will continue, possibly grow, during recession, Georgia State expert says
  63. Small peptide found to stop lung cancer tumor growth in mice
  64. Anti-estrogens may offer protection against lung cancer mortality
  65. Conflicting Diagnostic Reports
  66. Functional profiling in stage IV NSCLC: A phase II trial of individualized therapy
  67. Radiation Pneumonitis
  68. More Effective Treatment for Leptomeningeal Carcinomatous in Lung Cancer?
  69. False Positive PET scan?
  70. Testing lung tumors tailors chemotherapy
  71. Smoking influences gene function, scientists say
  72. Potential Role of Flow Cytometry in the Diagnosis of Small Cell Carcinoma
  73. Lung Cancer: Who is a Candidate for Surgery?
  74. The Histoculture Drug Response Assay (HDRA)
  75. Iressa Improves PFS for Metastatic Lung Cancer with EGFR Mutations
  76. New lung cancer research finds half of advanced lung cancer patients receive chemothe
  77. Risk of NSCLC cited as possible complication of HRT
  78. People with specific kind of lung cancer respond to new targeted treatment
  79. Eating a variety of fruit cuts lung cancer risk
  80. The National Lung Screening Trial
  81. Crizotinib in NSCLC
  82. Growth Factor Receptor Gene Amplification in Squamous Cell Lung Cancer
  83. Megace and Weight Gain
  84. Smart-pill alternative to PCI (prophylactic cranial irradiation)
  85. Is There Success With Both Iressa and Tarceva?
  86. Researchers Explain Why Cancer 'Smart Drugs' May Not Be So Smart
  87. An example of new generation of clinical trials (BATTLE)
  88. Yervoy (ipilimumab) in NSCLC
  89. Can Tamoxifen enhance the effect of Tarceva
  90. New way to halt small cell lung cancer
  91. If EGFR and ALK status is Negative what medicine we should give to halt the tumor
  92. Gene-expression signatures not ready for prime-time
  93. The EGFR Signaling Pathway
  94. Skeletal Muscle Metastasis Secondary to Lung Cancer
  95. Neuroendocrine carcinoma of the lung
  96. Is Avastin good for elderly NSCLC patient with brain mets?
  97. Combination Epigenetic Therapy Has Efficacy in Patients Refractory Advanced NSCLC
  98. Oligometastases in Lung Cancer
  99. The Problem with KRAS Mutation Studies
  100. Phase 2 Trial of Zybrestat in Non-small Cell Lung Cancer
  101. Chasing Gene Mutations
  102. Wnt Signaling Inhibitors
  103. The role of genomic testing for predicting response to targeted therapy
  104. Maintenance therapy with Alimta (pemetrexed): PARAMOUNT study
  105. Matching Targeted Therapies To Tumor's Specific Gene Mutations
  106. Chemoradiotherapy Improves Survival for Elderly With NSCLC
  107. SNaPshot Technology
  108. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
  109. Anti-angiogenic activity and VEGF pathway inhibition of Tarceva
  110. Alimta!!!
  111. Gene Mutation vs Chromosomal Theory of Cancer
  112. Functional Profiling to Select Chemotherapy in Advanced or Metastatic NSCLC
  113. Brain irradiation in lung cancer
  114. Driver Mutations and Passenger Mutations on the road to cancer
  115. The scope of PGx testing: What is pharmacogenomic testing?
  116. U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutat
  117. CSHL Identify Cells That Promote Formation of Lethal Lung Metastases
  118. EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors
  119. Assay Results and Bayes' Theorem
  120. Small-cell lung cancer: an unusual therapeutic approach - surgery
  121. For Smokers, Low Levels of Vitamin D May Lead to Cancer
  122. Ganetespib Showed Activity in KRAS-Mutant NSCLC as Monotherapy and in Combinations
  123. Controversies in NSCLC
  124. FDA Approves Companion Genetic Diagnostic Test for Tarceva in NSCLC
  125. Liquid biopsy for tumor genotyping may be on the horizon?
  126. Immunotherapy: A prematurely-abandoned treatment option
  127. Foundation Medicine and the Big Barrier to Cancer Genomic Sequencing
  128. Batch Processing of tumor biopsies for cell markers
  129. Predictive utility of VeriStrat to determine survival outcome with Tarceva vs chemo
  130. Simply finding a mutation
  131. Examination of Xalkori activity in human tumor primary culture micro-spheroids
  132. How Molecular Profiling Works
  133. FDA Approves Zykadia (Ceritinib) for ALK-Positive Lung Cancer
  134. Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in NSCLC
  135. Two Lung Cancer Trials Fall Short of Goal
  136. Surgical biopsies in the service of better treatment
  137. Combination microRNA therapy
  138. Genomic Profiling for Lung Cancer: the Good, the Bad and the Ugly
  139. The Many Faces of Lung Cancer